Equillium, a biotech developing therapies for graft-versus-host-disease and severe asthma, raised $65 million by offering 4.7 million shares at $14, the low end of the $14 to $16 range. At pricing, the La Jolla, CA-based company will command a market value of $235 million. Equillium plans to list on the Nasdaq under the symbol EQ. Jefferies, Leerink Partners and Stifel acted as lead managers on the deal.
